Eledon Pharmaceuticals Reports Promising Phase 1b Trial Results

Eledon Pharmaceuticals ( (ELDN) ) has issued an update.

On August 6, 2025, Eledon Pharmaceuticals announced updated data from its ongoing Phase 1b trial evaluating tegoprubart for preventing organ rejection in kidney transplant patients. The data, presented at the World Transplant Congress, showed promising results with tegoprubart demonstrating stable kidney function and improved graft survival compared to the current standard of care. Tegoprubart was well tolerated with no significant adverse effects, and the company anticipates topline results from its Phase 2 BESTOW trial in November 2025.

The most recent analyst rating on (ELDN) stock is a Buy with a $20.50 price target. To see the full list of analyst forecasts on Eledon Pharmaceuticals stock, see the ELDN Stock Forecast page.

Spark’s Take on ELDN Stock

According to Spark, TipRanks’ AI Analyst, ELDN is a Underperform.

Eldon Pharmaceuticals faces significant financial challenges with a lack of revenue and persistent losses, reflected in its low financial performance score. The stock’s technical indicators point towards a bearish trend, further compounded by a negative P/E ratio and no dividend yield. The company’s future hinges on successful product development or strategic financial interventions to improve its financial and market position.

To see Spark’s full report on ELDN stock, click here.

More about Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions. The company’s lead investigational product is tegoprubart, an anti-CD40L antibody, which is being explored for its therapeutic potential in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS).

Average Trading Volume: 545,857

Technical Sentiment Signal: Sell

Current Market Cap: $187.4M

See more insights into ELDN stock on TipRanks’ Stock Analysis page.